AstraZeneca Dips Toes in Emerging Class of Cancer Drugs — Market Talk
AstraZeneca's investment in Summit Therapeutics gives the U.K. drugmaker skin in the game of an emerging class of cancer drugs, UBS analysts say in a research note. Miami-based Summit is developing a cancer drug called ivonescimab that blocks two proteins known as PD-1 and VEGF. Evidence is emergin…